Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-05-05

AUTHORS

Ko-Ming Lin, Tien-Tsai Cheng, Jing-Chi Lin, Chung-Jen Chen

ABSTRACT

The aim of this study was to investigate treatment response and hepatic safety of anti-tumor necrosis factor-α therapy among patients with concomitant rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection. We reviewed the charts of 101 consecutive RA patients who were eligible for anti-TNF-α therapy in the Chiayi Branch of Chang Gung Memorial Hospital. Group A patients were sero-positive for anti-HCV antibodies and had HCV RNA but were negative for hepatitis B surface antigen (HBsAg). Group B (the control group) patients were sero-negative for both anti-HCV antibodies and HBsAg. Response to anti-TNF-α treatment was assessed by calculating disease activity score at 28 joints (DAS28) at baseline and 5, 8, and 11 months after the start of TNF-α antagonist therapy. Percentage change in DAS28 from baseline to month 5 was 21.36 ± 8.01 % in group A and 26.98 ± 10.43 % in group B (p = 0.011). However, there was no obvious difference in treatment response between groups at other time points. Anti-TNF-α therapy was discontinued within 1 year of starting treatment in two subjects in group A and 4 in group B. Response to anti-TNF-α was better in group B than in group A at 5 months, but there was no substantial difference in response at the 1-year evaluation. Although the study sample was small, our results suggest that the safety of anti-TNF-α therapy is similar in RA patients with and without concomitant HCV infection. More... »

PAGES

1039-1046

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10067-015-2962-6

DOI

http://dx.doi.org/10.1007/s10067-015-2962-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046227787

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25939523


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adalimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents, Non-Steroidal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azathioprine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemical and Drug Induced Liver Injury", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etanercept", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxychloroquine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoxazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leflunomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfasalazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan", 
          "id": "http://www.grid.ac/institutes/grid.145695.a", 
          "name": [
            "Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Chiayi, Taiwan", 
            "Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lin", 
        "givenName": "Ko-Ming", 
        "id": "sg:person.01020313221.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020313221.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan", 
          "id": "http://www.grid.ac/institutes/grid.145695.a", 
          "name": [
            "Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Tien-Tsai", 
        "id": "sg:person.01070251433.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070251433.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan", 
          "id": "http://www.grid.ac/institutes/grid.145695.a", 
          "name": [
            "Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Chiayi, Taiwan", 
            "Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lin", 
        "givenName": "Jing-Chi", 
        "id": "sg:person.01026276540.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026276540.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Kaohsiung Medical University Hospital, No.100, Tz You 1st Road, 807, Kaohsiung City, Taiwan, Republic of China", 
          "id": "http://www.grid.ac/institutes/grid.412027.2", 
          "name": [
            "Department of Internal Medicine, Kaohsiung Medical University Hospital, No.100, Tz You 1st Road, 807, Kaohsiung City, Taiwan, Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Chung-Jen", 
        "id": "sg:person.01042542222.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042542222.54"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-009-1149-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040588854", 
          "https://doi.org/10.1007/s10067-009-1149-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-05-05", 
    "datePublishedReg": "2015-05-05", 
    "description": "The aim of this study was to investigate treatment response and hepatic safety of anti-tumor necrosis factor-\u03b1 therapy among patients with concomitant rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection. We reviewed the charts of 101 consecutive RA patients who were eligible for anti-TNF-\u03b1 therapy in the Chiayi Branch of Chang Gung Memorial Hospital. Group A patients were sero-positive for anti-HCV antibodies and had HCV RNA but were negative for hepatitis B surface antigen (HBsAg). Group B (the control group) patients were sero-negative for both anti-HCV antibodies and HBsAg. Response to anti-TNF-\u03b1 treatment was assessed by calculating disease activity score at 28 joints (DAS28) at baseline and 5, 8, and 11\u00a0months after the start of TNF-\u03b1 antagonist therapy. Percentage change in DAS28 from baseline to month 5 was 21.36\u2009\u00b1\u20098.01\u00a0% in group A and 26.98\u2009\u00b1\u200910.43\u00a0% in group B (p\u2009=\u20090.011). However, there was no obvious difference in treatment response between groups at other time points. Anti-TNF-\u03b1 therapy was discontinued within 1\u00a0year of starting treatment in two subjects in group A and 4 in group B. Response to anti-TNF-\u03b1 was better in group B than in group A at 5\u00a0months, but there was no substantial difference in response at the 1-year evaluation. Although the study sample was small, our results suggest that the safety of anti-TNF-\u03b1 therapy is similar in RA patients with and without concomitant HCV infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10067-015-2962-6", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "TNF-\u03b1 therapy", 
      "hepatitis C virus infection", 
      "concomitant rheumatoid arthritis", 
      "C virus infection", 
      "anti-HCV antibodies", 
      "rheumatoid arthritis", 
      "group A", 
      "RA patients", 
      "antagonist therapy", 
      "virus infection", 
      "treatment response", 
      "group B", 
      "tumor necrosis factor-\u03b1 antagonist therapy", 
      "TNF-\u03b1 antagonist therapy", 
      "Chang Gung Memorial Hospital", 
      "hepatitis B surface antigen", 
      "concomitant HCV infection", 
      "anti-tumor necrosis", 
      "consecutive RA patients", 
      "Group A patients", 
      "group B patients", 
      "Disease Activity Score", 
      "case series study", 
      "B surface antigen", 
      "hepatic safety", 
      "\u03b1 treatment", 
      "HCV infection", 
      "HCV RNA", 
      "B patients", 
      "A patients", 
      "activity score", 
      "Memorial Hospital", 
      "series study", 
      "patients", 
      "surface antigen", 
      "month 5", 
      "therapy", 
      "percentage change", 
      "time points", 
      "infection", 
      "study sample", 
      "arthritis", 
      "baseline", 
      "antibodies", 
      "months", 
      "treatment", 
      "response", 
      "safety", 
      "DAS28", 
      "HBsAg", 
      "TNF", 
      "hospital", 
      "necrosis", 
      "antigen", 
      "scores", 
      "differences", 
      "study", 
      "subjects", 
      "obvious differences", 
      "substantial differences", 
      "group", 
      "aim", 
      "years", 
      "charts", 
      "RNA", 
      "joints", 
      "evaluation", 
      "start", 
      "changes", 
      "samples", 
      "results", 
      "branches", 
      "point"
    ], 
    "name": "Tumor necrosis factor-\u03b1 antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study", 
    "pagination": "1039-1046", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046227787"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10067-015-2962-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25939523"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10067-015-2962-6", 
      "https://app.dimensions.ai/details/publication/pub.1046227787"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_660.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10067-015-2962-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10067-015-2962-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10067-015-2962-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10067-015-2962-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10067-015-2962-6'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      21 PREDICATES      124 URIs      115 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10067-015-2962-6 schema:about N07f26561d0bb4174bfe12b3211a8c1c1
2 N1616ac7afc8e4bf8ad59494524cbe643
3 N1b919b57f9f94587998c42256a12833c
4 N228958d4cf88424eb8766a0012faac17
5 N23cba4dd00df43758285f07b94d62b4a
6 N2e94d343c9d84f78a862931391283a8f
7 N318058254fa64c7b94b4ad6b11519854
8 N3212edf8f10e45c08fdb30e914a5c814
9 N3d16ec6134e74043a0602db4072f1510
10 N4233be504e664df79f5ed2e2239f42c6
11 N4949ef29f4ac4b04a1e270214e8c67cc
12 N4f9c72b1535b45bab2388059b8c7208c
13 N6ce010f05756446d9b530d4102656323
14 N777c2ed666af430bafe5e38334c47211
15 Na8f710c7504049e992f007bb8cd3c83a
16 Nafedf75f92af42b28cb0d41edd1c6ed3
17 Nbda76d36f5374f0d8c1a42af691e5e18
18 Nc1d4f392bd77411a91ed05867c76f3af
19 Nd2f7cdf103e9436e856f860f54a4e9ac
20 Nd957420711424822982d39cd20c1f12b
21 Nd98e113fe4054afb9e747b02e19c6375
22 Nde83b6ef34ca4e1fa0694c6529c86b63
23 Nf2ba1d91e1d842e7888d5f617b385fea
24 Nf8ac4bddc35f43248496a03c4e66db62
25 Nfaee857388de49779ab8b173e1b72006
26 anzsrc-for:11
27 anzsrc-for:1103
28 schema:author Nb44942224d8b442684c090ef2ac4e806
29 schema:citation sg:pub.10.1007/s10067-009-1149-4
30 schema:datePublished 2015-05-05
31 schema:datePublishedReg 2015-05-05
32 schema:description The aim of this study was to investigate treatment response and hepatic safety of anti-tumor necrosis factor-α therapy among patients with concomitant rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection. We reviewed the charts of 101 consecutive RA patients who were eligible for anti-TNF-α therapy in the Chiayi Branch of Chang Gung Memorial Hospital. Group A patients were sero-positive for anti-HCV antibodies and had HCV RNA but were negative for hepatitis B surface antigen (HBsAg). Group B (the control group) patients were sero-negative for both anti-HCV antibodies and HBsAg. Response to anti-TNF-α treatment was assessed by calculating disease activity score at 28 joints (DAS28) at baseline and 5, 8, and 11 months after the start of TNF-α antagonist therapy. Percentage change in DAS28 from baseline to month 5 was 21.36 ± 8.01 % in group A and 26.98 ± 10.43 % in group B (p = 0.011). However, there was no obvious difference in treatment response between groups at other time points. Anti-TNF-α therapy was discontinued within 1 year of starting treatment in two subjects in group A and 4 in group B. Response to anti-TNF-α was better in group B than in group A at 5 months, but there was no substantial difference in response at the 1-year evaluation. Although the study sample was small, our results suggest that the safety of anti-TNF-α therapy is similar in RA patients with and without concomitant HCV infection.
33 schema:genre article
34 schema:isAccessibleForFree false
35 schema:isPartOf N7bef1c7377f2419cbd6a3a61ad2fb6e3
36 Na25cebc6d8a54333933a6a40e46d53d5
37 sg:journal.1093299
38 schema:keywords A patients
39 B patients
40 B surface antigen
41 C virus infection
42 Chang Gung Memorial Hospital
43 DAS28
44 Disease Activity Score
45 Group A patients
46 HBsAg
47 HCV RNA
48 HCV infection
49 Memorial Hospital
50 RA patients
51 RNA
52 TNF
53 TNF-α antagonist therapy
54 TNF-α therapy
55 activity score
56 aim
57 antagonist therapy
58 anti-HCV antibodies
59 anti-tumor necrosis
60 antibodies
61 antigen
62 arthritis
63 baseline
64 branches
65 case series study
66 changes
67 charts
68 concomitant HCV infection
69 concomitant rheumatoid arthritis
70 consecutive RA patients
71 differences
72 evaluation
73 group
74 group A
75 group B
76 group B patients
77 hepatic safety
78 hepatitis B surface antigen
79 hepatitis C virus infection
80 hospital
81 infection
82 joints
83 month 5
84 months
85 necrosis
86 obvious differences
87 patients
88 percentage change
89 point
90 response
91 results
92 rheumatoid arthritis
93 safety
94 samples
95 scores
96 series study
97 start
98 study
99 study sample
100 subjects
101 substantial differences
102 surface antigen
103 therapy
104 time points
105 treatment
106 treatment response
107 tumor necrosis factor-α antagonist therapy
108 virus infection
109 years
110 α treatment
111 schema:name Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study
112 schema:pagination 1039-1046
113 schema:productId N25c0f48c24c6499e9fc12b3a7f998565
114 N28f467926af947069b9d277e70ac22c5
115 Nc5e2a6899b944617a11148687f7918ed
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046227787
117 https://doi.org/10.1007/s10067-015-2962-6
118 schema:sdDatePublished 2022-09-02T15:58
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher Nbb4732316b9047b1a124485395267e8c
121 schema:url https://doi.org/10.1007/s10067-015-2962-6
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N07f26561d0bb4174bfe12b3211a8c1c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Chemical and Drug Induced Liver Injury
127 rdf:type schema:DefinedTerm
128 N10530293e2d3437abb3a0128226352b5 rdf:first sg:person.01070251433.66
129 rdf:rest N6f9eadbdd8414d87a9ef35736a995f95
130 N1616ac7afc8e4bf8ad59494524cbe643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Methotrexate
132 rdf:type schema:DefinedTerm
133 N1b919b57f9f94587998c42256a12833c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Retrospective Studies
135 rdf:type schema:DefinedTerm
136 N228958d4cf88424eb8766a0012faac17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Aged
138 rdf:type schema:DefinedTerm
139 N23cba4dd00df43758285f07b94d62b4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 N25c0f48c24c6499e9fc12b3a7f998565 schema:name dimensions_id
143 schema:value pub.1046227787
144 rdf:type schema:PropertyValue
145 N28f467926af947069b9d277e70ac22c5 schema:name pubmed_id
146 schema:value 25939523
147 rdf:type schema:PropertyValue
148 N2e94d343c9d84f78a862931391283a8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antirheumatic Agents
150 rdf:type schema:DefinedTerm
151 N318058254fa64c7b94b4ad6b11519854 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Leflunomide
153 rdf:type schema:DefinedTerm
154 N3212edf8f10e45c08fdb30e914a5c814 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hydroxychloroquine
156 rdf:type schema:DefinedTerm
157 N3d16ec6134e74043a0602db4072f1510 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cohort Studies
159 rdf:type schema:DefinedTerm
160 N4233be504e664df79f5ed2e2239f42c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Drug Therapy, Combination
162 rdf:type schema:DefinedTerm
163 N4949ef29f4ac4b04a1e270214e8c67cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Adalimumab
165 rdf:type schema:DefinedTerm
166 N4f9c72b1535b45bab2388059b8c7208c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Arthritis, Rheumatoid
168 rdf:type schema:DefinedTerm
169 N6ce010f05756446d9b530d4102656323 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Male
171 rdf:type schema:DefinedTerm
172 N6f9eadbdd8414d87a9ef35736a995f95 rdf:first sg:person.01026276540.11
173 rdf:rest Ned8fb025236a429da846aa157b881e6e
174 N777c2ed666af430bafe5e38334c47211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Cyclosporine
176 rdf:type schema:DefinedTerm
177 N7bef1c7377f2419cbd6a3a61ad2fb6e3 schema:volumeNumber 34
178 rdf:type schema:PublicationVolume
179 Na25cebc6d8a54333933a6a40e46d53d5 schema:issueNumber 6
180 rdf:type schema:PublicationIssue
181 Na8f710c7504049e992f007bb8cd3c83a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Treatment Outcome
183 rdf:type schema:DefinedTerm
184 Nafedf75f92af42b28cb0d41edd1c6ed3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Etanercept
186 rdf:type schema:DefinedTerm
187 Nb44942224d8b442684c090ef2ac4e806 rdf:first sg:person.01020313221.77
188 rdf:rest N10530293e2d3437abb3a0128226352b5
189 Nbb4732316b9047b1a124485395267e8c schema:name Springer Nature - SN SciGraph project
190 rdf:type schema:Organization
191 Nbda76d36f5374f0d8c1a42af691e5e18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Hepatitis C, Chronic
193 rdf:type schema:DefinedTerm
194 Nc1d4f392bd77411a91ed05867c76f3af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Isoxazoles
196 rdf:type schema:DefinedTerm
197 Nc5e2a6899b944617a11148687f7918ed schema:name doi
198 schema:value 10.1007/s10067-015-2962-6
199 rdf:type schema:PropertyValue
200 Nd2f7cdf103e9436e856f860f54a4e9ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Azathioprine
202 rdf:type schema:DefinedTerm
203 Nd957420711424822982d39cd20c1f12b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Anti-Inflammatory Agents, Non-Steroidal
205 rdf:type schema:DefinedTerm
206 Nd98e113fe4054afb9e747b02e19c6375 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Immunosuppressive Agents
208 rdf:type schema:DefinedTerm
209 Nde83b6ef34ca4e1fa0694c6529c86b63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Sulfasalazine
211 rdf:type schema:DefinedTerm
212 Ned8fb025236a429da846aa157b881e6e rdf:first sg:person.01042542222.54
213 rdf:rest rdf:nil
214 Nf2ba1d91e1d842e7888d5f617b385fea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Middle Aged
216 rdf:type schema:DefinedTerm
217 Nf8ac4bddc35f43248496a03c4e66db62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Tumor Necrosis Factor-alpha
219 rdf:type schema:DefinedTerm
220 Nfaee857388de49779ab8b173e1b72006 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Female
222 rdf:type schema:DefinedTerm
223 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
224 schema:name Medical and Health Sciences
225 rdf:type schema:DefinedTerm
226 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
227 schema:name Clinical Sciences
228 rdf:type schema:DefinedTerm
229 sg:journal.1093299 schema:issn 0770-3198
230 1434-9949
231 schema:name Clinical Rheumatology
232 schema:publisher Springer Nature
233 rdf:type schema:Periodical
234 sg:person.01020313221.77 schema:affiliation grid-institutes:grid.145695.a
235 schema:familyName Lin
236 schema:givenName Ko-Ming
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020313221.77
238 rdf:type schema:Person
239 sg:person.01026276540.11 schema:affiliation grid-institutes:grid.145695.a
240 schema:familyName Lin
241 schema:givenName Jing-Chi
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026276540.11
243 rdf:type schema:Person
244 sg:person.01042542222.54 schema:affiliation grid-institutes:grid.412027.2
245 schema:familyName Chen
246 schema:givenName Chung-Jen
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042542222.54
248 rdf:type schema:Person
249 sg:person.01070251433.66 schema:affiliation grid-institutes:grid.145695.a
250 schema:familyName Cheng
251 schema:givenName Tien-Tsai
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070251433.66
253 rdf:type schema:Person
254 sg:pub.10.1007/s10067-009-1149-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040588854
255 https://doi.org/10.1007/s10067-009-1149-4
256 rdf:type schema:CreativeWork
257 grid-institutes:grid.145695.a schema:alternateName Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
258 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan
259 schema:name Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
260 Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Chiayi, Taiwan
261 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Chiayi, Taiwan
262 rdf:type schema:Organization
263 grid-institutes:grid.412027.2 schema:alternateName Department of Internal Medicine, Kaohsiung Medical University Hospital, No.100, Tz You 1st Road, 807, Kaohsiung City, Taiwan, Republic of China
264 schema:name Department of Internal Medicine, Kaohsiung Medical University Hospital, No.100, Tz You 1st Road, 807, Kaohsiung City, Taiwan, Republic of China
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...